4 results
Approved WMOCompleted
Primary: Efficacy of FF/GW642444 100/25 mcg once daily in comparison with that of FP/salmeterol 250/50 mcg twice daily during 24 weeks.Secundary: Safety and tolerability.
Approved WMOCompleted
The primary objective of this study is to evaluate efficacy and safety. Secondary objectives: PK, PK-PD.
Approved WMORecruiting
To attenuate the impact and duration of delayed graft funtion by dampening schemia reperfusion injury
Approved WMORecruiting
This study will explore the safety, tolerability, PK, immunogenicity, PD, and preliminary efficacy of RO7428731, in participants with newly diagnosed and recurrent EGFRvIII-positive GBM.